2724-LB: Cohort Study–Association between Food Desert Residence and Hyperlipidemia

Introduction and Objective: Understand the association between residence in food deserts and hyperlipidemia prevalence. Determine if point-of-care lipid screening motivated positive lifestyle changes. Methods: Adults residing in Solano County who attended Touro University mobile clinics between December 2024 and February 2025 were included. Finger-stick POC lipid panel was obtained, and participants self-reported their residential ZIP code. Food desert status was determined using census tract classifications from the USDA Food Access Research Atlas. Participants were contacted after two weeks for a follow-up survey to assess perceived usefulness of POC lipid testing and whether it motivated them to make changes to diet, exercise, or schedule follow-up with a PCP. The association between food desert residence and hyperlipidemia was evaluated using chi-square testing and logistic regression, reported as odds ratios (OR) and 95% confidence intervals. Results: Of the 270 participants screened, 158 (58%) resided in food deserts. Hyperlipidemia was identified in 46% of participants living in food deserts versus 32% in non-food deserts (p=0.02). Residence in food deserts was associated with increased odds of hyperlipidemia (OR 1.81, 95% CI 1.09-3.00). 42% of participants completed the survey; all respondents found POC screening useful and 76.5% reported a positive lifestyle change. Conclusion: Residence in food desert ZIP codes was associated with higher prevalence and increased odds of hyperlipidemia, suggesting structural determinants such as food access may contribute to disparities in cardiometabolic risk. Community-based POC lipid screening may serve as a valuable tool for increasing awareness and motivating lifestyle modification in underserved populations. Disclosure M. Panganamala: None. Y. Vonteddu: None. J. Shubrook: Advisory Panel; Current; Abbott Diabetes. Other - Doc Care Deputy EditorConsensus panel-liver health, screening early stage T1d, Technology in primary care; Current; American Diabetes Association. Advisory Panel; Current; Bayer AG, Boehringer Ingelheim International GmbH. Consultant; Ended; Corcept Therapeutics. Advisory Panel; Ended; Idorsia Pharmaceuticals Ltd. Advisory Panel; Current; Insulet Corporation. Advisory Panel; Ended; Madrigal Pharmaceuticals, Inc. Consultant; Current; Novo Nordisk, Sanofi. S. Ahmed: None.